Egypt Pharmaceuticals & Healthcare Report Q2 2013
Published by Business Monitor International
on Mar 4, 2013
, 105 pages
PDF - Download Now with 3 Quarterly Updates format - Delivered by download
BMI View: Geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies such as Egypt may be a favourable strategy for any multinational drugmaker. However,despite our forecast for steady growth in theEgyptianpharmaceutical market,it is vitalthat companiesrecognise the risks. Downside risks to our forecast, in addition to the country's state of political and economic flux,are:the patent cliff, pricing, higher domestic drug production output and adiversificationofdrugs availableat competitive prices in the generic drug sector.